Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition containing amlodipine, atorvastatin and folic acid as well as new application thereof

A technology of atorvastatin and amlodipine, applied in the direction of drug combination, active ingredients of heterocyclic compounds, blood diseases, etc., to achieve the effect of reducing Hcy damage, solving clinical blanks, and reducing Hcy

Inactive Publication Date: 2009-12-02
北京奥萨医药研究中心有限公司 +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At the same time, there is still levoamlodipine on the market, which has a good curative effect.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Example 1: The curative effect of amlodipine atorvastatin folic acid on hyperHcyemia rat model

[0019] 1. Method

[0020] For modeling, 75 male rats of 250-300 g were randomly divided into 5 groups, 15 rats / group. One group was given normal feed, and the other group was given high-methionine feed for 12 consecutive weeks.

[0021]Grouping and administration Each group was given amlodipine+atorvastatin (0.5mg+1mg / kg), folic acid (0.08mg / kg), amlodipine+atorvastatin+folic acid (0.5+1+0.08mg / kg), and the other two groups of model group and normal group were given the same amount of normal saline.

[0022] 2. Results

[0023] The results showed that, compared with the normal group, Hcy in the high methionine feed group was significantly increased. The amlodipine + atorvastatin group had no significant effect on Hcy, and folic acid could significantly reduce the Hcy level; the amlodipine + atorvastatin + folic acid group could significantly reduce the Hcy level, which ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a drug composition containing amlodipine, atorvastatin and folic acid and a new application thereof in preparing drugs for treating the HHCY-hyperhomocysteinemia and the elevated homocysteine. The composition of the amlodipine or a levoamlodipine, the atorvastatin and the folic acid can further reduce the Hcy level, and the effect is superior to that of single drug, so that the composition of the amlodipine or the levoamlodipine, the atorvastatin and the folic acid can not only lower the Hcy level, but also has synergetic effect on reducing the Hcy damages. The composition of the invention is a selection for treating Hcy, which provides a more effective treatment protocol for treating high homocysteine. The invention belongs to the pharmaceutical field.

Description

technical field [0001] The invention relates to the use of a pharmaceutical composition containing amlodipine or levamlodipine, atorvastatin and folic acid in the preparation of medicines for treating hyperhomocysteinemia or diseases with elevated homocysteine. belongs to the field of pharmacy. Background technique [0002] As early as 1969, it was hypothesized that homocysteine ​​(Hcy, a sulfur-containing amino acid) might be a risk factor for cardiovascular disease. Since then, a large number of studies have accumulated objective evidence that plasma homocysteine Cystine levels are closely related to the risk of cardiovascular disease (CVD) and other systemic diseases. [0003] A large number of different types of studies have confirmed that the level of plasma homocysteine ​​is independent of traditional risk factors such as hypertension and hyperlipidemia. A 5 μmol / L increase in Hcy increases the risk of stroke by 59% (OR, 1.59; 95% CI, 1.30- 1.95), the risk of deep ve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4422A61K31/40A61K31/519A61P43/00A61P7/00
Inventor 秦献辉王文艳于多徐希平
Owner 北京奥萨医药研究中心有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com